The Recall Desk

FDA (Drugs) recall action 67344

Merck & Co Inc recalled 4 products on 2014-05-14

The FDA (Drugs) publishes a recall like this one as 4 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 4 pages.

Products
4
Announced
2014-05-14
Critical
0
Units
79,389

Why these products were recalled

This recall of LIPTRUZET is being initiated due to packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

Defective Container; some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

The agency’s own wording, quoted from the enforcement report.

The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.

States named across these recalls

1–4 of 4

  • LowFDA (Drugs)··2014-05-14

    Merck Recalls Liptruzet Tablets Due to Packaging Defects

    Merck & Co. is recalling Liptruzet tablets because packaging defects allowed air and moisture to enter, potentially reducing product effectiveness.

    Product
    Liptruzet (ezetimibe and atorvastin) tablets,10 mg/20 mg, a) 30 count blister (NDC 66582-321-30), b) 90 count blister (NDC 66582-321-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
    Category
    Distribution
    1 state
  • LowFDA (Drugs)··2014-05-14

    Merck Recalls Liptruzet Tablets Due to Packaging Defects

    Merck is recalling Liptruzet tablets because outer packaging defects allowed air and moisture to enter, potentially affecting product effectiveness.

    Product
    Liptruzet (ezetimibe and atorvastin) tablets,10 mg/40 mg, a) 30 count blister (NDC 66582-322-30), b) 90 count blister (NDC 66582-322-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
    Category
    Distribution
    1 state
  • LowFDA (Drugs)··2014-05-14

    Merck Recalls Liptruzet Tablets Due to Packaging Defects

    Merck & Co. is recalling Liptruzet tablets because packaging defects allowed air and moisture to enter, potentially affecting product effectiveness.

    Product
    Liptruzet (ezetimibe and atorvastin) tablets,10 mg/10 mg, a) 30 count blister (NDC 66582-320-30), b) 90 count blister (NDC 66582-320-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
    Category
    Distribution
    1 state
  • LowFDA (Drugs)··2014-05-14

    Merck Recalls Liptruzet Tablets Due to Defective Outer Packaging

    Merck is recalling Liptruzet tablets because defective outer foil pouches may allow air and moisture to enter, potentially affecting product effectiveness.

    Product
    Liptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister (NDC 66582-323-30), b) 90 count blister (NDC 66582-323-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
    Category
    Distribution
    1 state